Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK/PD of Osivelotor in Sickle Cell Disease
NCT04983264Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of osivelotor in sickle cell disease (SCD) (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, Number of Participants With Clinically Significant Physical Examination Findings and 3 more. Started May 2021; status: completed.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04983264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983264.